Overview

PRC-063 in an ADULT Workplace Environment

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the time of onset and time course of efficacy over 16 hours of PRC-063 compared to placebo in adults diagnosed with ADHD in a simulated adult workplace environment (AWE) setting, as measured by the PERMP (an individually-adjusted math test) at pre-dose, 1.0, 2.0, 5.0, 8.0, 11.0, 14.0 and 16.0 hours post-dose.
Phase:
Phase 3
Details
Lead Sponsor:
Rhodes Pharmaceuticals, L.P.
Collaborator:
Purdue Pharma LP